GO
Loading...

Medicine

More

  • Pfizer Finding Innovation At Medivation Wednesday, 3 Sep 2008 | 10:32 AM ET
    Lilly Effient

    In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).

  • No Vindication For Vytorin; Victory for Sciele Tuesday, 2 Sep 2008 | 1:30 PM ET

    While I was on the "New England Journal of Medicine" Web site yesterday preparing my reports for today about the embargoed articles, I noticed a banner ad at the top of the homepage from Eli Lilly saying something along the lines of, "Coming Soon: Effient (Prasugrel)."

  • For Widely Used Drug, Question of Usefulness Lingers Tuesday, 2 Sep 2008 | 4:51 AM ET

    When the Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that it had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug, the New Yor Times reported.

  • Hurricane Lurking For Merck & Schering-Plough? Friday, 29 Aug 2008 | 11:34 AM ET

    This won't be much of an end-of-summer holiday weekend for the folks at Merck and Schering-Plough. That's because early Tuesday morning (5am ET) the detailed results of the so-called SEAS study will be presented at a scientific conference in Germany. This is the test of MRK and SGP's cholesterol drug Vytorin, which showed a higher incidence of cancer among the patients taking the pill.

  • Merck's Charm Offensive Thursday, 28 Aug 2008 | 10:49 AM ET
    Gardasil Advertisment

    In the current monster-sized issue of Vogue, my producer, Ruth, while killing time on the Delta shuttle on our way from New York to Boston for a shoot this week, uncovered a blogworthy story buried in the hundreds and hundreds and hundreds of pages of fashion ads. It represents a whole new idea in the world of direct-to-consumer (DTC) drug advertising.

  • When It Rains Risk, It Pours Wednesday, 27 Aug 2008 | 12:01 PM ET

    Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals and Cell Genesys, much lower. After the closing bell Tuesday, Bristol-Myers Squibb and Pfizer had an announcement to make...

  • Drug Safety Updates For Elan, Biogen, Amylin & Lilly Tuesday, 26 Aug 2008 | 11:23 AM ET
    Byetta Needle

    After the closing bell Monday, Eli Lilly and Amylin Pharmaceuticals announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Why?

  • AstraZeneca's Flu Campaign Season Begins Monday, 25 Aug 2008 | 12:35 PM ET
    Flu Vaccination Button

    Talk about timely direct-to-consumer advertising. Last week ,I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political.

  • Of Football, Pfizer and Pharma Friday, 22 Aug 2008 | 11:31 AM ET

    As we head into my last free summer weekend before USC's football season kicks off, I wanted to clean out the Pharma's Market mailbox. (Actually I was looking for an apropos-of-nothing excuse to mention the Trojans.)

  • The Genentech Guessing Game Thursday, 21 Aug 2008 | 12:18 PM ET

    Shares of Genentech are taking another little breather after rising to around 99 bucks on speculation that a higher offer is coming from Roche. Analyst guestimates of the ultimate takeout price -- if, indeed there is one -- are generally above a hundred dollars a share.

  • ImClone's Sam Is Steppin' Out Tuesday, 19 Aug 2008 | 12:02 PM ET
    Insider trader Sam Waksal, toting a bag from Smythson, a luxury leather shop.

    A photographer for the "New York Post" snapped this picture last night of a nattily dressed Sam Waksal returning to a halfway house in the Bronx after going on a little shopping trip.

  • Anatomy of The Amylin Drug Warning Monday, 18 Aug 2008 | 6:00 PM ET

    It was my turn to man the CNBC Alerts Desk earlier today from 9am ET to 1 pm ET. I had finished blogging about the "Barron's bounce" Amylin Pharmaceuticals was getting, based on the speculative mention about it being a potential takeout target for Eli Lilly. Then, I look up at the screen and see AMLN is absolutely tanking...

  • AstraZeneca Gives FluMist A Shot In The Arm Monday, 18 Aug 2008 | 2:33 PM ET
    Flumist Advertisement

    Ads for flu vaccines have traditionally been confined to PSAs, health and media alerts. So that's why I was surprised to see this colorful full-page ad in The New York Times this weekend for FluMist from AstraZeneca/MedImmune. Why..?

  • Abbott's Covering The Bases Thursday, 14 Aug 2008 | 1:28 PM ET

    The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.

  • Dendreon's Provenge Study, And Takeout Target Updates Wednesday, 13 Aug 2008 | 11:52 AM ET

    Before I get to my favorite biotech saga, there are noteworthy, if not newsworthy, press releases out this morning from two takeout targets. Genentech put out a statement from the special independent board committee that's been appointed to handle the Roche buyout offer.

  • Elan On Eight-Eight-Oh-Eight, Etc. Friday, 8 Aug 2008 | 11:47 AM ET
    Elan

    The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.

  • ImClone's Poetic Justice Thursday, 7 Aug 2008 | 11:11 AM ET
    Sam Waksal, former CEO of ImClone Systems

    A week after Bristol-Myers Squibb made its move for ImClone Systems, one of the people who made the biotech infamous could be getting out of the clink.

  • Xanadu For Xanodyne Tuesday, 5 Aug 2008 | 11:32 AM ET
    Xanodyne

    We reporters who cover biopharma are inundated with story pitches from companies and PR folks. Most of them go immediately into the electronic trash bin. But I couldn't let this one go so fast

  • ImClone Wants To Clone Itself? Monday, 4 Aug 2008 | 12:33 PM ET

    Just before the opening bell this morning ImClone Systems put out a clearly Carl Icahn-inspired press release regarding last week's $60-a-share buyout offer from Bristol-Myers Squibb.

  • So Much For The Summer Doldrums Friday, 1 Aug 2008 | 11:14 AM ET

    What a crazy week, right? Monday, Amgen had a huge upside revenue and earnings surprise. Tuesday, the Food and Drug Administration issued its new restrictions on the use of Amgen's anemia drugs in certain cancer patients. Later that same day, Elan and Wyeth released the big Alzheimer's drug test results.